Moreover, IFN-β and ribavirin therapy is associated with a low incidence of adverse effects, such as depression [12], thrombocytopenia, and leukocytopenia [13], compared with IFN-α or Peg-IFN-α and ribavirin therapy. This evidence concerns the gene IFNA1 and Thrombocytopenia.